Mr Bilal Alkhaffaf

Consultant General Surgeon


Clinical Interests

  • Cancer of the oesophagus and stomach
  • Weight-loss surgery
  • Sleeve gastrectomy
  • Gastric bypass
  • Gastric balloon
  • Acid reflux
  • Hiatus hernia
  • Achalasia
  • Gallstones
  • Abdominal and groin hernias

Useful links

Professional Memberships

  • Fellow of the Royal College of Surgeons, Edinburgh
  • Association of Upper Gastrointestinal Surgeons of Great Britain & Ireland
  • British Obesity & Metabolic Surgery Society
  • The European Society of Surgical Oncology
  • BASO – The Association for Cancer Surgery
  • Faculty of Surgical Trainers

Call 0808 101 0337

Personal profile

Bilal Alkhaffaf is a consultant laparoscopic and upper gastrointestinal surgeon at Salford Royal NHS Foundation Trust – the country’s largest specialist upper gastrointestinal surgical centre. He specialises in the treatment of conditions affecting the upper gastrointestinal tract which includes oesophageal and gastric cancer, obesity, benign oesophageal and gastric disorders, acid reflux, hiatus hernia, achalasia, gallstones and hernias.

Mr Alkhaffaf has a specialist interest in advanced minimally invasive (keyhole) surgery and has developed his expertise by visiting international surgical centres of excellence in the United States, South Korea, The Netherlands as well as a number of leading organisations within the United Kingdom. He prioritises the delivery of excellent medical care for all his patients and believes that this should be achieved hrough a relationship based on trust, clear communication and an empathetic approach.Consultant Q&A Cancer Care

Mr Alkhaffaf is active in the field of research and holds the position of ‘Honorary Senior Lecturer’ at the University of Manchester. His research activities have resulted in his award of a prestigious ‘NIHR Doctoral Research Fellowship‘. Mr Alkhaffaf has a particular interest in the way surgical outcomes are reported and is currently working with international experts to make research in gastric cancer treatment more relevant to patients.

Year qualified: